 |
 |
Pharmaceutical Industry to Address Potential of Stem Cells to Treat Neurodegenerative and Other Diseases Monday September 8, 8:17 am ET NEW YORK, Sept. 8 /PRNewswire/ -- Data from recent studies on CNS regeneration using adult stem cells will be presented by the pharmaceutical industry at an upcoming conference, signaling the first step towards the industry's willingness to pursue therapeutics in the hotly debated field. Stem cells have the ability to migrate to diseased or damaged area of the brain, showing capacities to repair them in some studies. This demonstrates the potential for alleviating degenerative neurological diseases such as Parkinson's and Lou Gehrig's. The pharmaceutical industry will present recent findings in this area at an upcoming meeting in Princeton, NJ. The meeting is the among most comprehensive on the topic of stem cell research, as it addresses new advances in the field from academia and industry, while providing businesses with financial and legal perspectives. The pharmaceutical industry will also address bioethical considerations during the plenary. Over the course of its two highly successful annual events, the conference has attracted stem cell scientists from pharmaceutical and biotechnology companies, as well as CEO's, CSO's, investors, and others seeking to make contact with the development of the new and promising science. For a list of past/current attendees, or for sponsorship/exhibitor opportunities, please contact Steve J. Kuperberg at (212) 967 0095 ext. 261, or via email at [log in to unmask] SOURCE: Strategic Research Institute L.P. / Yahoo News (press release) http://biz.yahoo.com/prnews/030908/nym062_1.html * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn